Jump to content
Powered by

Pharmaceutics

The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

  • Article - 08/08/2016

    Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…

  • Article - 02/08/2016

    An early phase clinical study involving thirty-six Huntington’s disease (HD) patients is currently underway to investigate whether a method called gene silencing can cure the disease. If the gene that causes the disease can be turned off, it would be the first step towards a treatment that not only fights symptoms but actually treats the causes of HD, hence providing a cure.

  • Article - 27/07/2016

    Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.

  • Article - 21/07/2016

    Secondary hop compounds appear to have a positive effect on the immune system and therefore have the potential to be used for the treatment and prevention of cancer. However, the bioavailability of hop compounds in the human body is relatively poor. Researchers from Hohenheim and Tübingen are therefore looking for a way to increase their absorption rate.

  • Article - 19/07/2016

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

  • Article - 11/07/2016

    Natural killer cells kill tumour cells by injecting the protein HMGB1, which blocks the production of cellular energy by aerobic respiration. Researchers from Heidelberg have elucidated this previously unknown cancer defence mechanism and are now in the process of developing a new immunotherapy for treating cancer patients.

  • Company profile - 05/07/2016

    The idea of analysing tissue samples automatically sounds more of a pipe dream than anything else. However, it already happens. HS-Analysis GmbH's ability to interpret tissue samples automatically is driving new drug development a decisive step forward.

  • Company profile - 27/06/2016

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

  • Article - 20/06/2016

    Researchers from Heidelberg have shown that instead of fighting cancer cells, macrophages of the innate immune system promote the growth of metastases in people with metastatic colorectal cancer. They have also shown that a signal inhibitor used to treat HIV infections reactivates macrophages so that they gain the ability to destroy cancer cells. A clinical phase I study has confirmed the antitumoral effects of this drug.

  • Article - 16/06/2016

    It is estimated that as many as one million secondary plant metabolites can be used as medical agents. Plants produce these compounds to aid their growth and development as well as to discourage herbivores from eating them. However, it is still very difficult, or even impossible, to produce secondary plant metabolites industrially. Researchers from the Karlsruhe Institute of Technology (KIT) are now developing a microfluidic bioreactor to make…

  • Dossier - 14/06/2016

    The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene editing or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/pharma